CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California. Show more

505 Coast Boulevard South, La Jolla, CA, 92037, United States

https://calcimedica.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

13.66M

52 Wk Range

$1.87 - $36.00

Previous Close

$2.00

Open

$2.00

Volume

52,447

Day Range

$1.94 - $2.04

Enterprise Value

4.171M

Cash

18.62M

Avg Qtr Burn

-4.62M

Insider Ownership

18.53%

Institutional Own.

57.51%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Auxora™ Details Acute Pancreatitis	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Auxora™ Details Asparaginase-induced pancreatic toxicity	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Auxora™ Details Acute Kidney Injury (AKI)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Auxora/Zegocractin (Zegocractin) (CRAC Channel Inhibitor) Details Pulmonary Arterial Hypertension	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CM5480 (CRAC Channel Inhibitor) Details Pulmonary Arterial Hypertension	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB-102 (Pan-VEGF inhibitor) Details Eye disease , Wet age-related macular degeneration , Age-related macular degeneration	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB-102 (Pan-VEGF inhibitor) Details Diabetes, Eye disease , Diabetic macular edema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.